New, even more effective HPV vaccine in sight

September 11, 2013
New, even more effective HPV vaccine in sight

A recently published paper by the Department of Immunodermatology at the Medical University of Vienna has unveiled a second-generation prophylactic HPV vaccine. In future, this will not only protect against the majority of genital high and low-risk types, but also the types that are responsible for the development of skin warts.

The results of the pre-clinical study, which raises hopes for the future development of a broadly effective vaccine against the Human Papillomavirus (HPV), have recently been published in the highly respected magazine Journal of Investigative Dermatology. The study was carried out by Christina Schellenbacher and a team led by Reinhard Kirnbauer from the Department of Immunodermatology at the MedUni Vienna (headed by Georg Stingl), with the collaboration of working groups from the Vienna University of Veterinary Medicine, the University of Malmö and the Johns Hopkins University (in Baltimore, USA). The next stage involves the vaccine's evaluation in clinical trials.

Unlike with the vaccines that have been available previously, which contain two to four antigens, the researchers adopted a different approach: they put together an individual, new antigen (RG1-VLP) from the 's main capsid protein L1 and auxiliary L2. In laboratory studies, this vaccine demonstrated significantly broader effectiveness against high and low-risk types of HPV compared to the vaccines that are available currently.

New vaccine also effective against hand and foot warts

Unless previous vaccines, the new also protects for the first time against cutaneous, or skin-based, types of HPV. These types of HPV cause hand and foot warts as well as flat warts, primarily among children, but also in adults. These skin changes can cause significant problems, especially for immunosuppressed patients.

Vaccination makes sense for children

The results of the study also raise the prospect of administering the vaccine to children. According to the researchers, this would help effectively prevent the development of during childhood and later infections with genital viruses.

Reinhard Kirnbauer, who is also already the inventor of the existing HPV16 vaccine and therefore the key element of the new vaccine, also highlights two further advantages: "The vaccine has been formulated as a singular antigen (RG1-VLP), offering a prospective economic advantage compared to the existing licensed vaccines and a nine-in-one vaccine that is currently undergoing clinical trials. HPV-VLP vaccines also have an excellent safety profile, which means we are now keen to push ahead with the evaluation of the in clinical studies."

Explore further: 1 in 5 boys got HPV shot in first year recommended

More information: Schellenbacher, C. et al. Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses, Journal of Investigative Dermatology. DOI: 10.1038/jid.2013.253

Related Stories

1 in 5 boys got HPV shot in first year recommended

August 29, 2013
A new report offers a first look at how many boys are getting shots designed to protect girls from cervical cancer. Health officials say the number getting vaccinated so far is a good start.

HPV vaccination to provide even more protection in future against infections

April 17, 2013
At present over one hundred strains of the human papillomavirus (HPV) are known, fourteen of which can trigger cancer. The HPV vaccinations currently in use provide protection from 70 percent of these cancers. "With the next ...

Hidden strains of HPV found in 'virus-negative' genital warts

July 11, 2013
There are 170 established HPV types. Cancerous human papillomavirus (HPV) viruses are the main cause of cervical cancer, and are found in close to 100% of cervical tumors.

Significant decline of genital warts in young women

July 20, 2012
(Medical Xpress) -- The incidence of condyloma or genital warts (GW) is significantly declining in young women, according to a novel register study from Karolinska Institutet. The researchers suggest that this recent development ...

How cervical cancer vaccines came to be

January 19, 2013
(HealthDay)—The cervical cancer vaccine has turned into one of the biggest success stories in the field.

Report: Teen HPV vaccination rate still lagging

July 25, 2013
(AP)—Disappointed health officials say only about half of teenage girls have gotten a controversial vaccine against cervical cancer—a rate that's changed little in three years.

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.